Navigation Links
Gene Study Throws Up New Targets for Leishmaniasis

Gene sleuths believe they may have identified potential chinks in the parasite that causes leishmaniasis, a disfiguring and sometimes fatal disease that afflicts some 12 million people around the world . Their comparison of three species of protozoa that cause most cases of leishmaniasis could be a boon for drug engineers, whose budgets for tackling this neglected disease are already slender.

British-led scientists compared the genetic code of Leishmania major, which causes the cutaneous form of leishmaniasis, with those of L. infantum and L. braziliensis, which cause the more dangerous, visceral form of the disease, also called kala-azar. What struck the researchers was that these parasites were very similar genetically, even though they cause very different types of disease.

Each genome has more than 8,000 genes, but only 200 of them differ across the three species. "The degree of similarity between these species was unexpected," said Deborah Smith, a professor at the University of York, northern England. "Perhaps only a few parasite genes are important in determining which type of disease develops after infection, and the host genome plays a major role in clinical outcome."

Another surprise was to find a small number of genes that have never been spotted before. Fellow investigator Chris Peacock described these novel genes as a "short cut" that could help the pharmaceutical quest. "Given their lack of similarity to human genes, they present a limited repertoire of potential targets for drug and vaccine development, allowing researchers to optimise the use of limited resources."

The Leishmania parasite is transmitted in the saliva of sandflies, who tuck in to a blood meal on humans, wild animals and dogs. Around 350 million people in 88 countries are "at risk" of the disease, whose incidence has risen sharply over the past decade, according to the Wellcome Trust Sanger Institute, a British medical research ch arity that led the genome comparison.

The frontline affordable drug, sodium stiboglucomate, marketed as Pentostam, is running into bad resistance problems, leaving many doctors with the option of more expensive treatment that, in the case of visceral leishmaniasis, can cost up to 150 dollars for a four-week course. Cutaneous and mucosal leishmaniasis results in painful, crater-like lesions on the skin.

Visceral leishmaniasis, which affects the spleen and liver, causing fever and weight loss, is fast becoming an opportunistic disease among people whose immune systems have been compromised by the AIDS virus. The study appears on Sunday in the journal Nature Genetics.


'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 13, 2017 , ... While it’s often important to take certain medications during ... Austin, Texas, has identified a solution. , She developed a prototype for MOTION LIGHT-UP ... such, it eliminates the need to turn on a light when taking medication during ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017 Halo Labs announces the European launch of their ... HORIZON at MIBio 2017 in Cambridge, U.K ... matter in biopharmaceutical samples with unprecedented speed and sensitivity while using ... Backgrounded Membrane Imaging. ... subvisible particle analysis system ...
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
Breaking Medicine Technology: